{
  "source": "PA-Notification-Balversa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1284-7\nProgram Prior Authorization/Notification\nMedication Balversa® (erdafitinib)\nP&T Approval Date 6/2019, 5/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nBalversa (erdafitinib) is a kinase inhibitor indicated for the treatment of adult patients with\nlocally advanced or metastatic urothelial carcinoma (mUC) with susceptible fibroblast growth\nfactor receptor 3 (FGFR3) genetic alterations whose disease has progressed on or after at least\none line of prior systemic therapy.\nLimitations of Use:\nBalversa is not recommended for the treatment of patients who are eligible for and have not\nreceived prior PD-1 or PD-L1 inhibitor therapy.\nThe National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium also\nrecommends the use of Balversa in the treatment of salivary gland tumor, pancreatic\nadenocarcinoma, non-small cell lung cancer, invasive breast cancer, and cholangiocarcinoma.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Balversa will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Urothelial Carcinoma\n1. Initial Authorization\na. Balversa will be approved based on ALL of the following criteria:\n(1) Diagnosis of urothelial carcinoma\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is one of the following:\n(a) Locally advanced\n(b) Metastatic\n-AND-\n(3) Presenc",
    " the following criteria:\n(1) Diagnosis of urothelial carcinoma\n© 2025 UnitedHealthcare Services, Inc.\n1\n-AND-\n(2) Disease is one of the following:\n(a) Locally advanced\n(b) Metastatic\n-AND-\n(3) Presence of FGFR3 genetic alterations\n-AND-\n(4) Disease has progressed on or after at least one line of prior systemic therapy\n[e.g., platinum-based chemotherapy (e.g., cisplatin, carboplatin), immune\ncheckpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab)]\n-AND-\n(5) One of the following:\n(a) Patient has received prior systemic therapy containing an immune\ncheckpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab)\nOR-\n(b) Patient is not eligible for immune checkpoint inhibitor therapy (e.g.,\npembrolizumab, nivolumab, avelumab)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Balversa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Balversa\ntherapy.\nAuthorization will be issued for 12 months.\nC. Salivary Gland Tumor\n1. Initial Authorization\na. Balversa will be approved based on ALL of the following criteria:\n(1) Diagnosis of salivary gland tumor\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n2\n(2) Disease is one of the following:\n(a) Recurrent\n(b) Unresectable\n(c) Metastatic\n-AND-\n(3) Presence of FGFR genetic alterations\n-AND-\n(4) Disease has progressed on or after at least one line of prior systemic therapy\n[e.g., platinum-based chemotherapy (e.g., cisplatin, carboplatin)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Balversa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Balversa\ntherapy.\nAuthorization will be issued for 12 months.\nD. Pancreatic Adenocarcinoma\n1. Initial Authorization\na. Balversa will be approved based on ALL of the following criteria:\n(1) Diagnosis of pancreatic adenocarcinoma\n-AND-\n(2) Disease is one of the following:\n(a) Locally advanced\n(b) Metastatic\n(c) Recurrent\n-AN",
    "rsa will be approved based on ALL of the following criteria:\n(1) Diagnosis of pancreatic adenocarcinoma\n-AND-\n(2) Disease is one of the following:\n(a) Locally advanced\n(b) Metastatic\n(c) Recurrent\n-AND-\n(3) Presence of FGFR genetic alterations\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Balversa will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n3\n(1) Patient does not show evidence of progressive disease while on Balversa\ntherapy.\nAuthorization will be issued for 12 months.\nE. Non-Small Cell Lung Cancer\n1. Initial Authorization\na. Balversa will be approved based on ALL of the following criteria:\n(1) Diagnosis of non-small cell lung cancer\n-AND-\n(2) Disease is metastatic\n-AND-\n(3) Presence of FGFR genetic alterations\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Balversa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Balversa\ntherapy.\nAuthorization will be issued for 12 months.\nF. Breast Cancer\n1. Initial Authorization\na. Balversa will be approved based on ALL of the following criteria:\n(1) Diagnosis of invasive breast cancer\n-AND-\n(2) Disease is metastatic\n-AND-\n(3) Presence of FGFR1-3 genetic alterations\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n4\n2. Reauthorization\na. Balversa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Balversa\ntherapy.\nAuthorization will be issued for 12 months.\nG. Cholangiocarcinoma\n1. Initial Authorization\na. Balversa will be approved based on ALL of the following criteria:\n(1) Diagnosis of cholangiocarcinoma\n-AND-\n(2) Disease is one of the following:\n(a) Unresectable\n(b) Metastatic\n-AND-\n(3) Presence of FGFR2 genetic alterations\n-AND-\n(4) Disease has progressed on or after both of the following:\n(a) Lytgovi (futibatinib)\n(b) Pemazyre (pemigatinib)\nAuthorization will be issued for ",
    "ND-\n(3) Presence of FGFR2 genetic alterations\n-AND-\n(4) Disease has progressed on or after both of the following:\n(a) Lytgovi (futibatinib)\n(b) Pemazyre (pemigatinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Balversa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Balversa\ntherapy.\nAuthorization will be issued for 12 months.\nH. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\n© 2025 UnitedHealthcare Services, Inc.\n5\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Balversa [package insert]. Horsham, PA: Janssen Products, LP; October 2024.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttp://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed March 21,\n2025\nProgram Prior Authorization/Notification - Balversa\nChange Control\n6/2019 New program.\n5/2020 Annual review. Updated reference.\n5/2021 Annual review. Updated references.\n5/2022 Annual review. Updated references.\n5/2023 Annual review with no changes to coverage criteria. Added state\nmandate footnote and updated references.\n5/2024 Annual review. Removed coverage for FGFR2 genetic alterations.\nAdded that first line of prior systemi",
    " with no changes to coverage criteria. Added state\nmandate footnote and updated references.\n5/2024 Annual review. Removed coverage for FGFR2 genetic alterations.\nAdded that first line of prior systemic therapy should contain an\nimmune checkpoint inhibitor, if eligible. Updated background and\nreferences.\n5/2025 Annual review. Added coverage criteria for salivary gland tumor,\npancreatic adenocarcinoma, non-small cell lung cancer, breast cancer,\nand cholangiocarcinoma. Updated background and references.\n© 2025 UnitedHealthcare Services, Inc.\n6"
  ]
}